A Phase 2a Trial Investigating the Safety and Tolerability of the Novel Cortical Enhancer IRL752 in Parkinson's Disease Dementia.
Svenningsson P, Odin P, Dizdar N, Johansson A, Grigoriou S, Tsitsi P, Wictorin K, Bergquist F, Nyholm D, Rinne J, Hansson F, Sonesson C, Tedroff J; IRL752 Collaborators.
Svenningsson P, et al. Among authors: grigoriou s.
Mov Disord. 2020 Jun;35(6):1046-1054. doi: 10.1002/mds.28020. Epub 2020 Mar 21.
Mov Disord. 2020.
PMID: 32198802
Clinical Trial.